(S)-Rivastigmine-d₄

Cat. No.: HY-W654336: Data Sheet Handling Instructions Technical Support

(S)-Rivastigmine-d₄ is deuterium labeled Rivastigmine. Rivastigmine (ENA 713 free base) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC₅₀s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease.

For research use only. We do not sell to patients.

(S)-Rivastigmine-d<sub>4</sub> Chemical Structure

(S)-Rivastigmine-d₄ Chemical Structure

Size	Price	Stock	Quantity
1 mg	USD 414	Get quote 2-4 weeks 2-4 weeks 2-4 weeks	2-4 weeks
5 mg		Get quote
10 mg		Get quote

Synthetic products have potential research and development risk.

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of (S)-Rivastigmine-d₄:

Rivastigmine In-stock

View All Cholinesterase (ChE) Isoform Specific Products:

View All Isoforms

AChE BChE

Biological Activity
Purity & Documentation
References
Customer Review

Description	(S)-Rivastigmine-d₄ is deuterium labeled Rivastigmine. Rivastigmine (ENA 713 free base) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC₅₀s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease^[1]^[2]^[3].
Molecular Weight	254.36
Formula	C₁₄H₁₈D₄N₂O₂
Unlabeled CAS	123441-03-2
SMILES	CCN(C(OC1=CC([C@@H](N(C([2H])([H])[2H])C([2H])([H])[2H])C)=CC=C1)=O)C
Shipping	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation	Data Sheet (267 KB) Handling Instructions (2659 KB)
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief] [2]. Qian-Sheng Yu, et al. Anticholinesterase activity of compounds related to geneserine tautomers. N-Oxides and 1,2-oxazines. J Med Chem. 2002 Aug 15;45(17):3684-91. [Content Brief] [3]. Helena Shifrin, et al. Rivastigmine alleviates experimentally induced colitis in mice and rats by acting at central and peripheral sites to modulate immune responses. PLoS One. 2013;8(2):e57668. [Content Brief] [4]. Han HJ, Lee JJ, Park SA et al. Efficacy and safety of switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch in patients with probable Alzheimer's disease. J Clin Neurol. 2011 Sep;7(3):137-42. [Content Brief] [5]. Raafat A Abdel-Aal, et al. Rivastigmine reverses aluminum-induced behavioral changes in rats. Eur J Pharmacol. 2011 Jun 1;659(2-3):169-76. [Content Brief]